Bridgeway Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bridgeway Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-260,200	Closed	-$26M	–	1349
2020 Q1	$26M	Sell	260,200 -56,500	-18%	-$7.31M	0.59%	55
2019 Q4	$47.3M	Sell	316,700 -56,700	-15%	-$7.72M	0.64%	47
2019 Q3	$47.8M	Hold	373,400	–	–	0.66%	49
2019 Q2	$53.2M	Buy	+373,400	New	+$50.2M	0.68%	47
2014 Q3	–	Sell	-54,700	Closed	-$8.04M	–	1497
2014 Q2	$8.04M	Buy	+54,700	New	+$7.59M	0.21%	88

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bridgeway Capital Management's JAZZ Position: Q2 2020 in Review

Bridgeway Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2020, closing a stake of 260,200 shares — an estimated $26M sold.

Bridgeway Capital Management first reported a position in JAZZ in Q2 2014 and held it in 5 quarters. The position peaked at $53.2M in Q2 2019. 384 funds tracked by Wall St. Rank hold JAZZ as of Q2 2020.

Bridgeway Capital Management reported no remaining Jazz Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Bridgeway Capital Management sold 260,200 Jazz Pharmaceuticals shares in Q2 2020, an estimated $26M.
Bridgeway Capital Management first reported a position in Jazz Pharmaceuticals in Q2 2014 and held it in 5 quarters.
Bridgeway Capital Management's Jazz Pharmaceuticals position peaked at $53.2M in Q2 2019.
384 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2020.

Based on Bridgeway Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.